Wolfson Group, a Scotland-based international consumer wellness company, is broadening access to its non-prescription weight management product PhenQ at a time when prescription GLP-1 medications are becoming increasingly common in American households. According to a June 2026 report from PwC, 21% of U.S. households included a current GLP-1 user as of May 2026, up from 9% in January 2025. That sharp rise has reshaped the weight management conversation, but Wolfson Group is stressing that nutrition, physical activity and non-prescription wellness products remain central to how many consumers approach weight management.
The company announced that PhenQ, its established consumer wellness brand, is now available through additional U.S. retail channels. PhenQ has an established presence on Amazon and recently became available through OneLavi.com, providing another online destination for American consumers. The expansion reflects Wolfson Group's broader U.S. strategy of developing multiple distribution channels while supporting its portfolio of wellness brands.
"The weight management market is evolving, and consumers have more choices than ever before," said the founder and CEO of Wolfson Group. "Prescription medications have become an important part of the conversation, but nutrition, physical activity and everyday lifestyle habits remain central to how people think about managing their weight. Our focus is on serving consumers in the non-prescription wellness market." The company emphasizes that PhenQ, as a non-prescription product, is distinct from prescription GLP-1 medications and should not be viewed as a substitute for prescribed medical treatments.
Why this matters: the rapid adoption of GLP-1 drugs is changing the weight management landscape, but it is also creating a larger, more fragmented marketplace in which consumers must navigate a mix of prescription treatments, nutritional products, fitness programs and lifestyle resources. Wolfson Group argues that this diversity creates opportunities for greater consumer education about the different product categories, their intended purposes and the importance of informed decisions. The company's portfolio spans weight management, cognitive wellness, gut health and men's wellbeing, including brands such as TestoPrime and NooCube, reflecting the multi-category nature of consumer wellness.
Wolfson Group continues to pursue additional U.S. retail opportunities following its participation in the September ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. The company said it will continue investing in consumer education, science-led brand development and expanded U.S. distribution as it builds its presence across the American wellness marketplace. For consumers, the key implication is that the weight management market is becoming more varied, and clear information about the differences between prescription and non-prescription options is increasingly important.
